BOEHRINGER-INGELHEIM
13.5.2020 14:02:08 CEST | Business Wire | Press release
Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.
“Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics for retinal diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The prospect of losing one’s sight is frightening. We are committed to transformational therapies that have the potential to succeed in preserving the health and vision of patients with retinal diseases, such as geographic atrophy.”
Utilizing antibody fragment-based technology, which retains the specificity of an antibody while significantly reducing the size of the molecule, may have significant advantages over traditional large molecule approaches for the treatment of retinal diseases, such as GA. When applied to the eye via intravitreal injection, high affinity antibody fragment therapies have the potential to reach the retinal pigment epithelial cells where degeneration is known to occur. This precise technology may help decrease the cellular stresses caused by AMD and prevent further loss of sight.
“Boehringer Ingelheim is one of the leading research and development companies in the field of biologics,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “This is an exciting partnership that brings together Boehringer Ingelheim’s development expertise and CDR-Life’s innovative antibody fragments to provide hope for people living with a blinding retinal disease. We look forward to advancing this project towards the clinic together with the Boehringer Ingelheim team.”
Boehringer Ingelheim takes a holistic approach to the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. By leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases, the company has built a comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
CDR-Life´s preclinical program utilizing antibody fragment-based technology complements this growing portfolio, providing an innovative approach to treat GA.
Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop certain compounds based on CDR-Life´s technology against a specific target and will be responsible for global development and commercialization. CDR-Life will be eligible to receive up to CHF 474.5 million in upfront and success-based milestone payments, as well as research funding and royalties on sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/geographicatrophycollabortationwithcdr-life
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vultr Expands European Footprint with 33rd Cloud Data Center Region in Milan, Italy19.5.2026 17:28:00 CEST | Press release
New region strengthens Vultr's commitment to affordable, high-performance cloud infrastructure and Europe's thriving open source and AI ecosystem Vultr, the world’s largest privately-held cloud infrastructure company, today announces the launch of its 33rd global cloud data center region in Milan, coinciding with AI Week 2026 at Fiera Milano Rho, where over 700 international speakers will gather for Europe's largest AI event. Vultr is a platinum sponsor and is also co-hosting the AI Agent Olympics Hackathon with over 1,000 participants. Milan becomes Vultr's ninth European cloud data center region, joining Amsterdam, Frankfurt, London, Madrid, Manchester, Paris, Stockholm, and Warsaw. This launch represents the company's latest expansion of a global network reaching 90% of the world's population within 2–40 milliseconds. Vultr’s cloud data center location will be delivering Vultr’s full-stack AI infrastructure, including Vultr’s flagship cloud compute offering, VX1, in addition to Vult
Global Millennial Capital Closes USD 100 Million IPO Opportunities Fund Focused on AI, Decentralized Financial Infrastructure, and Climate Technologies19.5.2026 17:16:00 CEST | Press release
Global Millennial Capital Ltd. (“GMCL”) today announced the final closing of its inaugural IPO Opportunities Fund at USD 100 million. Raised through a private placement with institutional and professional investors, the fund targets late-stage and special opportunities investments across mid-cap technology companies operating in high-growth sectors, including artificial intelligence, decentralized finance infrastructure, cybersecurity, digital infrastructure, enterprise software, and climate technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519513523/en/ Global Millennial Capital announces the successful final close of its USD 100 million IPO Opportunities Fund, reinforcing its commitment to investing in high-growth technology companies across artificial intelligence, digital infrastructure, cybersecurity, and next-generation financial systems. The fund is designed to capitalize on the increasing number of tech
Miro Takes Aim at the Gap Between AI Potential and Organizational Reality19.5.2026 16:00:00 CEST | Press release
At Canvas 26, Miro establishes its AI platform as the connective layer of the modern AI ecosystem — bringing together teams, agents, and the tools they already work in to turn individual AI productivity into organization-wide transformation Miro®, the AI Innovation Workspace for teams, has announced new innovations across its AI platform, reinforcing its position as the collaboration layer where people, context, and agents from every function converge to solve hard problems, make better decisions, and build the right thing faster. Major upgrades to Miro’s agentic AI tools — including Sidekicks and Flows — alongside new Connectors, help customers close the gap between individual AI productivity and organization-wide transformation. AI is reshaping the pace of work, but often teams are not realising the benefits. In many organizations, a gap has emerged between what individuals can now do and what companies can harness. The reason? Collaboration has fractured. Teams have moved from one m
Wolters Kluwer Medi-Span Selected to Provide Personalized Medication Decision Support at The Christie NHS Foundation Trust19.5.2026 15:30:00 CEST | Press release
Roll-out at largest EU cancer center marks first Medi-Span NHS implementation Wolters Kluwer Health has implemented its industry-leading medication decision support (MDS) solution, Medi-Span®, at the world-renowned specialist oncology center, The Christie NHS Foundation Trust. “The Christie is recognized globally for its excellence and commitment to delivering exceptional patient care,” says Israel Armstrong, Vice President for Medi-Span International at Wolters Kluwer Health. “We’re proud that our first Medi-Span implementation in the NHS should be with such a prestigious institution. We look forward to more collaborations that help streamline processes further and help clinical teams make the most highly informed decisions.” The Christie is a leading expert in cancer care, research and education and is the largest single-site cancer center in Europe. The Christie treats more than 60,000 patients a year and is the first facility in the UK to be accredited as a comprehensive cancer cen
Torq Acquires Jit to Unleash the First Enterprise AI SOC Context Graph—and Rewrite the Future of SecOps19.5.2026 15:00:00 CEST | Press release
With Jit Acquisition, Torq Catapults Enterprise SOCs Into a New Realm of Detailed Contextual Investigations That Drive Precision Decision-Making Torq, the established agentic security operations leader, today announced the acquisition of Jit, the Boston-based AI Context Graph cybersecurity pioneer. This move marks a dramatic leap forward for the Torq AI SOC Platform by ensuring agentic investigations are precisely informed via organization-specific contextual data. This shift redefines agentic reasoning, moving beyond static facts such as users, devices and their relationships, to prioritize live, dynamic contextual data overlaid on top, including business drivers, and the real-time state of the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519044833/en/ Instead of acting on fragmented data or having investigations triggered by a single alert, Torq AI operates with a unified, continuously-updated, contextual
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom